Xeroderma Pigmentosum With Ocular Surface Squamous Neoplasia: A Case Report

被引:1
作者
Malikireddy, Sravanthi [1 ]
机构
[1] Modern Eye Hosp, Ophthalmol, Chittoor, India
关键词
basal cell carcinoma (bcc); imiquimod; interferon therapy; ocular surface squamous neoplasia (ossn); xeroderma pigmentosum; TOPICAL IMIQUIMOD; BASAL;
D O I
10.7759/cureus.53204
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Xeroderma pigmentosum (XP) is a rare, autosomal recessive disorder characterized by defective DNA repair. Patients with this disorder are at increased risk of developing various oculocutaneous malignancies. We report a rare case of a child with XP with bilateral ocular surface squamous neoplasia (OSSN) and left eye (OS) medial canthal basal cell carcinoma (BCC). Ultrasound biomicroscopy and contrast -enhanced computed tomography (CECT) of the orbit showed intraocular extension with no orbital involvement. The patient was started on topical interferon therapy in both eyes for OSSN. Topical 5% imiquimod was started for BCC for eight hours a day and then washed off. During follow-up, there was no recurrence of tumors. Since ocular and cutaneous neoplasms tend to occur at an early age in XP with a high rate of recurrence and they tend to be more aggressive, multimodal therapy with long-term follow-up is more advantageous for these patients. Topical 5% imiquimod can be used as a treatment for periocular BCC as an alternative to excision.
引用
收藏
页数:7
相关论文
共 15 条
[1]   Ocular surface squamous neoplasia - A review [J].
Basti, S ;
Macsai, MS .
CORNEA, 2003, 22 (07) :687-704
[2]   Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial [J].
Bath-Hextall, Fiona ;
Ozolins, Mara ;
Armstrong, Sarah J. ;
Colver, Graham B. ;
Perkins, William ;
Miller, Paul S. J. ;
Williams, Hywel C. .
LANCET ONCOLOGY, 2014, 15 (01) :96-105
[3]  
Berger T, 2005, Andrews' Diseases of the Skin, Clinical Dermatology
[4]   Imiquimod - Its role in the treatment of cutaneous malignancies [J].
Bubna, Aditya Kumar .
INDIAN JOURNAL OF PHARMACOLOGY, 2015, 47 (04) :354-359
[5]   Ocular surface squamous neoplasia in xeroderma pigmentosum: clinical spectrum and outcome [J].
Gupta, Noopur ;
Sachdev, Ritika ;
Tandon, Radhika .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2011, 249 (08) :1217-1221
[6]   Ocular surface squamous neoplasia: management and outcomes [J].
Hollhumer, Roland ;
Williams, Susan ;
Michelow, Pamela .
EYE, 2021, 35 (06) :1562-1573
[7]  
Kalamkar Charudutt, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2016-215364
[8]   Subconjunctival/Perilesional Recombinant Interferon α2b for Ocular Surface Squamous Neoplasia A 10-Year Review [J].
Karp, Carol L. ;
Galor, Anat ;
Chhabra, Sachin ;
Barnes, Scott D. ;
Alfonso, Eduardo C. .
OPHTHALMOLOGY, 2010, 117 (12) :2241-2246
[9]   XERODERMA-PIGMENTOSUM - CUTANEOUS, OCULAR, AND NEUROLOGIC ABNORMALITIES IN 830 PUBLISHED CASES [J].
KRAEMER, KH ;
LEE, MM ;
SCOTTO, J .
ARCHIVES OF DERMATOLOGY, 1987, 123 (02) :241-250
[10]   OCULAR SURFACE SQUAMOUS NEOPLASIA [J].
LEE, GA ;
HIRST, LW .
SURVEY OF OPHTHALMOLOGY, 1995, 39 (06) :429-450